CLDX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Celldex reports positive Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 results for barzolvolimab, meeting all primary and key secondary endpointsSep 22, 2026
- Celldex presented long-term data showing sustained off-treatment improvement with barzolvolimab in CSU patients with angioedemaJun 15, 2026
- Celldex presented data showing barzolvolimab retreatment maintained strong efficacy in ColdU and symptomatic dermographism at AAAAI 2026Mar 2, 2026
- Celldex completes patient enrollment in the global Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticariaFeb 25, 2026
- Celldex initiates global Phase 3 registrational program of barzolvolimab in cold urticaria and symptomatic dermographismDec 9, 2025